Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Gray Sheet

Executive Summary

AngioDynamics leadership transition: Eamonn Hobbs, president and CEO of interventional radiology and oncology device maker AngioDynamics, says he will relinquish his role to become vice chairman of the board of directors, once the company has identified a "world class candidate" to lead the company. Hobbs, who co-founded the company 20 years ago, suggests, in a Dec. 3 announcement, that his strengths are primarily "entrepreneurial" and the firm now needs a leader to focus more exclusively on operational and administrative activities. In addition to a CEO, the firm is searching for an executive to manage its oncology/surgery business unit. On Dec. 9, it appointed Michael Sharp, formerly of image-based orthopedics company ConforMIS, as VP of regulatory, quality and clinical affairs

You may also be interested in...

AngioDynamics Taps Former CryoCath Chief Keltjens For CEO Slot

Incoming AngioDynamics CEO Jan Keltjens will draw on his 20-plus years of device industry leadership experience, including as former chief exec of CryoCath Technologies, to shepherd "the next level" of growth at the company

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts